
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Haemonetics Corp | NYSE:HAE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.71 | 1.10% | 65.28 | 66.62 | 64.25 | 64.50 | 1,494,583 | 01:00:00 |
Financial release accessible online
BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2024. The conference call and webcast can be accessed with the following information:
In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.
Direct link to 1Q FY25 Earnings Release:
https://haemonetics.gcs-web.com/static-files/1048427c-6709-4f0f-95d3-099b50780c50
A replay of the conference call and webcast will be available for one year beginning on August 8, 2024, at 11:00 a.m. ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
olga.guyette@haemonetics.com | david.trenk@haemonetics.com |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
josh.gitelson@haemonetics.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-1st-quarter-fiscal-year-2025-earnings-release-available-on-investor-relations-website-302217606.html
SOURCE Haemonetics Corporation
Copyright 2024 PR Newswire
1 Year Haemonetics Chart |
1 Month Haemonetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions